Epitalon + GHK-Cu + BPC-157
The compound with the best evidence is the one being used wrong.
GHK-Cu has more human data than almost anything in the skin category, and nearly all of it comes from creams. This stack injects it. Epitalon makes the biggest claim of the three and comes almost entirely from one laboratory in St Petersburg.
Three levels of ageing, in one set of vials.
The idea is that ageing shows up in more than one place, so a stack should cover more than one. Epitalon is the cellular claim, aimed at telomeres, the caps on the ends of chromosomes that shorten each time a cell divides. GHK-Cu is the visible one, covering skin, collagen and how you look. BPC-157 covers repair, so injuries that took a week at thirty and take a month at fifty.
It is the broadest anti-ageing combination in circulation, and the one most often described as a foundation to build on.
Two of the three have appeal well beyond the ageing story.
GHK-Cu is the strongest of them. It firms skin, softens fine lines, fades dark spots and supports wound healing, and it has more human evidence behind it than almost anything else in the skin category. It is in mainstream cosmetics on the strength of that evidence, which separates it from every other compound on this site.
Epitalon is run in short courses of a week or two instead of continuously, which is the main practical thing to know about it. Its pineal origin is the reason people take it at night.
BPC-157 brings the largest animal literature of any compound here, consistent across tendon, ligament, gut and surgical healing models. That is genuine preclinical weight, and it is the reason this compound appears in more stacks on this site than any other.
None of them fails the same way.
Most stacks on this site share one problem across their members. This one has a different problem for each.
wrong route
never shared
Those are three separate kinds of gap and they do not add up to one verdict. A compound with strong topical evidence being injected is in a different position from one whose trial was never published, and both differ from one whose literature comes almost entirely from a single group.
Volume is not the issue. Concentration is.
Epitalon has been studied for forty years and produced hundreds of papers. Almost all of them came out of one institute.[2]
A finding reproduced by twenty laboratories is a different kind of fact from one reported many times by the same one, however careful that laboratory is. Independent replication has been limited, though a 2025 study from Brunel University and a 2026 cell study have started to change that.[4]
The specific gaps are checkable. There are no registered or completed human clinical trials. There is no pharmacokinetic study in any species, meaning nobody has published what happens to the compound after it enters a body: how much reaches the blood, how long it lasts, where it goes.[3] For something injected for decades, that absence is hard to explain.
The Russian clinical work in elderly patients is the most striking part of the record and the hardest to lean on. Those studies were not run to Western standards: patients were not split between groups by chance, nobody was kept unaware of who got what, and there was no dummy-treatment group to compare against.[2]
One concern has been named and it came from the research literature rather than from anyone reporting harm. Almost every cancer cell switches telomerase back on, the enzyme that rebuilds telomeres, and it is part of how they keep dividing without limit. One analysis looked at cancer cells grown in a dish and found Epitalon lengthening their telomeres by a second route and flagged that this could in theory help those cells survive.[2] No study has shown Epitalon causes cancer. The work to rule it out has not been done either. The Epitalon and DSIP page covers this in full.
Three compounds, no shared mechanism.
One thing this stack gets right that several others do not: the three compounds do not duplicate each other. A copper peptide signalling collagen, a gastric protein fragment associated with blood vessel growth, and a four-amino-acid peptide from the pineal gland aimed at telomeres are three genuinely different claims.
Compare that with the growth hormone stacks, where two compounds routinely sit on the same receptor. Redundancy is not the objection here.
What is missing is any study of the combination. No trial has given all three together, or any two of them, in people or in animals. This is our own searching. It is not a systematic review, and we will correct this page for anyone who can point to a trial.
The one hard number anywhere on whether stacking adds up comes from a different combination entirely. In the CagriSema trial, two compounds on genuinely separate pathways delivered 88% of what simple addition would predict. Three compounds on separate pathways have no particular reason to beat that, and nobody has measured it.
Three compounds, three different positions.
None of the three has FDA approval for any use.
BPC-157 went through a review by the Pharmacy Compounding Advisory Committee in July 2026, the panel that advises the FDA on what compounding pharmacies may work with. That review has not been finalised into a rule, and turning a recommendation into a rule runs eight to twenty-four months when it happens at all.
GHK-Cu is widely sold in cosmetics and is not restricted there. Putting it on skin and injecting it are different regulatory questions, and only the first is settled.
Epitalon has no US regulatory position at all, which is different from being restricted. It has never been through a review because it has never been submitted for one.
One advantage worth naming: none of the three is on the World Anti-Doping Agency prohibited list. That separates this stack from GLOW, KLOW and Wolverine, all of which contain TB-500 and are therefore a doping violation for any tested athlete.
What people ask about the longevity stack
Does Epitalon lengthen telomeres in people?
Unknown. In cell cultures it does switch on telomerase, the enzyme that rebuilds telomeres. Animal work points the same way. But no controlled trial in healthy people, checked by other laboratories, has shown that injecting it lengthens telomeres by any amount worth having. The idea is plausible and the human evidence has not confirmed it.
Why is it a problem that one lab did most of the research?
Because replication is what turns a finding into a fact. Hundreds of papers from one institute is a different kind of evidence from twenty laboratories reaching the same conclusion separately. Independent work has begun to appear, including a 2025 Brunel University study and a 2026 cell study, and it is early. No major Western review of ageing biology currently treats the telomerase claim as settled.
Does the GHK-Cu skincare evidence apply if I inject it?
Not directly. GHK-Cu has more human evidence than almost anything in the skin category. Nearly all of it is topical, meaning creams and serums put on the skin and measured there. Injecting it is a different dose reaching different tissue, and no trial has tested whether the results transfer.
Do the three compounds overlap?
No, and that is unusual for a stack this size. Collagen signalling, blood vessel growth and telomere maintenance are three three different claims with no shared pathway. Redundancy is the objection to several other stacks on this site, and it is not the objection here. The objection here is that nobody has studied the combination.
Could Epitalon raise cancer risk?
It is a question the research literature has raised and not answered. Telomerase reactivation is a near-universal feature of cancer cells and part of how they divide without limit. One analysis found Epitalon extending telomeres in cancer cells grown in a dish, through a different route and flagged that this could theoretically help those cells survive. No study has shown that Epitalon causes cancer, and the work to rule it out has not been done.
Is there a simpler version?
Dropping Epitalon leaves GHK-Cu and BPC-157, which is the cheapest stack we track at about $39 and removes the compound with the narrowest evidence base. Adding TB-500 instead gives you GLOW, sold premixed. Compare all of them here.
What this page is built on
The primary Russian literature on Epitalon is largely published in Russian and was not read for this page. Everything below is a secondary account of it, which is part of what the page describes.
- 01BPC-157 as PL 14736 under Pliva: Phase 1 safety in healthy volunteers, Phase 2 in ulcerative colitis, results unpublished. No published Phase 2 or Phase 3 randomised trial for any indication as of 2026.
- 02Review of Khavinson peptide bioregulators. Source for the concentration of publication in one institute, the methodological limitations of the elderly cohort studies, and the alternative telomere lengthening finding in cancer cell lines.
- 03Evidence quality assessment listing the specific gaps: no registered or completed human trials, no pharmacokinetic or pharmacodynamic studies in any species, no structural biology evidence for the proposed DNA interaction.
- 04Analysis of the foundational 2003 Khavinson cell culture study and later independent work, including a 2025 Brunel University study and a 2026 cell study.
- 05Peptide Decoding vendor pricing data, 13 September 2026. Lowest in-stock single-compound listings: Epitalon $23.16, GHK-Cu $19.49, BPC-157 $19.19.